Open AccessPatient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility
Author(s) -
L. Silvia Muñoz-Price,
Allison E. Reeme,
Blake W. Buchan,
Roberta T. Mettus,
Mustapha M. Mustapha,
Daria Van Tyne,
Ryan K. Shields,
Yohei Doi
Publication year - 2019
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00955-19
Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , ceftazidime , microbiology and biotechnology , avibactam , medicine , transmission (telecommunications) , biology , virology , bacteria , escherichia coli , pseudomonas aeruginosa , genetics , computer science , telecommunications , gene
We report patient-to-patient transmission ofEnterobacter hormaechei isolates with reduced susceptibility to ceftazidime-avibactam due to production of KPC-40, a variant of KPC-3 with a two-amino-acid insertion in the Ω-loop region (L167_E168dup). The index patient had received a prolonged course of ceftazidime-avibactam therapy, whereas the second patient had not received the agent and still became colonized with the KPC-40-producing strain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom